Virus glycoprotein nanodisc platform for vaccine design.

用于疫苗设计的病毒糖蛋白纳米盘平台

阅读:4
作者:Rantalainen Kimmo, Liguori Alessia, Ozorowski Gabriel, Flynn Claudia, Steichen Jon M, Swanson Olivia, Madden Patrick J, Baboo Sabyasachi, Phulera Swastik, Gharpure Anant, Lu Danny, Kalyuzhniy Oleksandr, Skog Patrick, Terada Sierra, Shil Monolina, Diedrich Jolene K, Georgeson Erik, Tingle Ryan, Eskandarzadeh Saman, Lee Wen-Hsin, Alavi Nushin, Goodwin Diana, Kubitz Michael, Amirzehni Sonya, Himansu Sunny, Sok Devin, Lee Jeong Hyun, Yates John R 3rd, Paulson James C, Crotty Shane, Schiffner Torben, Ward Andrew B, Schief William R
Transmembrane glycoproteins of enveloped viruses are the targets of neutralizing antibodies and essential vaccine antigens. mRNA-LNP technology allows in situ production of transmembrane glycoproteins upon immunization, but biophysical characterization of transmembrane antigens and in vitro analysis of post-immunization antibody responses typically rely on soluble proteins. Here, we present a methodological platform for assembling transmembrane glycoprotein vaccine candidates into lipid nanodiscs. We demonstrate the utility of the nanodiscs in HIV membrane proximal external region (MPER)-targeting vaccine development by binding assays using surface plasmon resonance (SPR), ex vivo B cell sorting with fluorescence-activated cell sorting (FACS), and by determining the structure of a prototypical HIV MPER-targeting immunogen nanodisc in complex with three broadly neutralizing antibodies (bnAbs), including the MPER bnAb 10E8, to 3.5 Ã by cryogenic electron microscopy (cryo-EM), providing a template for structure-based immunogen design for MPER. Overall, the platform offers a tool for accelerating the development of next-generation viral vaccines.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。